Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) saw unusually-strong trading volume on Friday . Approximately 701,723 shares changed hands during trading, an increase of 241% from the previous session’s volume of 205,566 shares.The stock last traded at $8.60 and had previously closed at $8.60.

A number of research analysts have recently commented on VTAE shares. Zacks Investment Research lowered shares of Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Wedbush restated an “outperform” rating and set a $23.00 price target on shares of Vitae Pharmaceuticals in a research report on Wednesday, May 25th. Wells Fargo & Co. restated a “buy” rating on shares of Vitae Pharmaceuticals in a research report on Friday, June 10th. Finally, JMP Securities lowered shares of Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Vitae Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $16.65.

The company’s market capitalization is $248.90 million. The stock has a 50-day moving average of $10.22 and a 200 day moving average of $8.63.

Vitae Pharmaceuticals (NASDAQ:VTAE) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.05. During the same quarter in the prior year, the company earned ($0.45) EPS. The business’s revenue for the quarter was down 98.0% compared to the same quarter last year. Equities research analysts predict that Vitae Pharmaceuticals Inc. will post ($1.64) EPS for the current fiscal year.

An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP acquired a new position in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned approximately 0.34% of Vitae Pharmaceuticals at the end of the most recent reporting period.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.